Core Viewpoint - AdaptHealth reported disappointing third-quarter results, missing analyst expectations for revenue, profitability, and guidance, leading to a nearly 10% drop in stock price [1][2][3] Financial Performance - Revenue for the third quarter was just under 806million,showingmarginalyear−over−yeargrowth[2]−Netincomewasapproximately23 million (0.15pershare),asignificantrecoveryfromalossofover454 million in the same quarter last year [2] - The earnings per share fell short of the consensus estimate of 0.19[3]GuidanceAdjustments−Thecompanyreviseditsfull−yearrevenueguidancedownto3.22 billion to 3.26billion,fromapreviousrangeofnearly3.26 billion to almost 3.32billion[4]−AdjustedEBITDAguidancewasalsoloweredto655 million to 675million,downfrom660 million to 700million[5]−Conversely,freecashflowguidancefor2024wasincreasedto175 million to 195million,upfromthepreviousrangeof160 million to $180 million [5]